Výsledky vyhledávání - "Mark W, Frohlich"

Abstract CT250: A Phase 1a/1b, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors

Autor: Roel Funke, Mark W. Frohlich, Mihaela C. Cristea, Samuel Ejadi, Alex Franzusoff, Mehrdad Abedi, Bartosz Chmielowski, Mitch Denker, Todd Stallings-Schmitt

Publikováno v: Cancer Research. 80:CT250-CT250

Introduction: Neoepitopes (neoE) derived from private tumor-exclusive mutations represent compelling targets for personalized TCR-T cell therapy. An ultra-sensitive and high-throughput process was developed to capture tumor mutation-targeted CD8 T ce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72df8cf58fd875fd4925f96339a6b42d
https://doi.org/10.1158/1538-7445.am2020-ct250

Zobrazit plný text záznamu

A phase Ia/Ib, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors

Autor: Todd Stallings-Schmitt, Mitch Denker, Mihaela C. Cristea, Bartosz Chmielowski, Mehrdad Abedi, Mark W. Frohlich, Samuel Ejadi, Alexis J. Franzusoff, Roel Funke

Publikováno v: Journal of Clinical Oncology. 38:TPS3151-TPS3151

TPS3151 Background: Neoepitopes (neoE) derived from private tumor-exclusive mutations represent compelling targets for personalized TCR-T cell therapy. An ultra-sensitive and high-throughput process was developed to capture tumor mutation-targeted CD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::945d9bff0820a034149cd6d6cb2ad968
https://doi.org/10.1200/jco.2020.38.15_suppl.tps3151

Zobrazit plný text záznamu

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

Autor: Celestia S. Higano, James Boyd Whitmore, Daniel P. Petrylak, Mark W. Frohlich, Eric J. Small, Philip W. Kantoff

Publikováno v: Prostate Cancer and Prostatic Diseases

BACKGROUND: Sipuleucel-T has demonstrated improved overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). This analysis examined the effect of sipuleucel-T on time to disease-related pain (TDRP) and time to first u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c21bf0c2bdff1f5c57fa315b52bd0bd
https://doi.org/10.1038/pcan.2014.21

Zobrazit plný text záznamu

Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial

Autor: Paul F. Schellhammer, Mark W. Frohlich, Philip W. Kantoff, James Boyd Whitmore, Robert B. Sims, Gerald W. Chodak

Publikováno v: Urology. 81:1297-1302

To explore the prognostic and predictive value of baseline variables in 512 patients with metastatic castration-resistant prostate cancer from the phase III Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial who were randomized to rec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56df7d7e66d743b85a6e58d25a73f9d5
https://doi.org/10.1016/j.urology.2013.01.061

Zobrazit plný text záznamu

Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer

Autor: Mark W. Frohlich, Allan J. Pantuck, Daniel J. George, Simon J. Hall, Laurence Klotz, James Boyd Whitmore, Robert B. Sims

Publikováno v: Journal of Urology. 186:877-881

We describe the safety of sipuleucel-T using an integrated analysis of 4 randomized, controlled studies in patients with prostate cancer.Adverse events, survival data and laboratory evaluations were examined for common, rare and latent events.In 5% o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bc6781194950c78914ce65102560722
https://doi.org/10.1016/j.juro.2011.04.070

Zobrazit plný text záznamu

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Autor: Philip W, Kantoff, Celestia S, Higano, Neal D, Shore, E Roy, Berger, Eric J, Small, David F, Penson, Charles H, Redfern, Anna C, Ferrari, Robert, Dreicer, Robert B, Sims, Yi, Xu, Mark W, Frohlich, Paul F, Schellhammer, J, Young

Publikováno v: New England Journal of Medicine. 363:411-422

Background Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. Methods In this double-blind, placebo-controlled, multi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d41701835f2db94568cec4ddc70b10a
https://doi.org/10.1056/nejmoa1001294

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání